16α-羟基雄甾酮 | 14167-49-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 16α-羟基雄甾酮
• 中文别名: 16Alpha-羟基雄甾酮
• 英文名称: 3α,16α-dihydroxy-5α-androstan-17-one
• 英文别名: 16α-hydroxyandrosterone；16α,3α-dihydroxy-5α-androstan-17-one；3α,16α-dihydroxy-5α-androstane-17-one；16|A-hydroxyandrosterone；(3R,5S,8R,9S,10S,13S,14S,16R)-3,16-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
• CAS: 14167-49-8
• 化学式: C₁₉H₃₀O₃
• 分子量: 306.445
• InChiKey: HLQYTKUIIJTNHH-LLIWRYSGSA-N

物化性质

• 溶解度：
  可溶于氯仿（轻微，超声处理）、DMSO（轻微）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  22
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  16α-羟基雄甾酮 在 二甲基亚砜 、 三乙胺 、 三氟乙酸酐 作用下， 生成 16α-hydroxy-5α-androstane-3,17-dione
  参考文献：
  名称：

  Kawada, Kenji; Gross, Raymond S.; Watt, David S., Synthetic Communications, 1989, vol. 19, # 5and6, p. 777 - 786

  摘要：

  DOI：

文献信息

• Constant Ion Loss Method for the Untargeted Detection of Bis-sulfate Metabolites
  作者：Malcolm D. McLeod、Christopher C. Waller、Argitxu Esquivel、Georgina Balcells、Rosa Ventura、Jordi Segura、Óscar J. Pozo

  DOI：10.1021/acs.analchem.6b03671

  日期：2017.2.7

  preferentially as the dianion ([M – 2H]2–) with a small contribution of the monoanion ([M – H]−). Product ion spectra generated from the [M – 2H]2– precursor ions were dominated by the loss of HSO4– to generate two product ions, that is, the ion at m/z 97 (HSO4–) and the ion corresponding to the remaining monosulfate fragment. Other product ions were found to be specific for some structures. As an example, the

  II期代谢物的非靶向检测是研究生物系统中药物代谢的关键问题。灵敏且选择性的质谱（MS）技术与超高效液相色谱（UHPLC）系统相结合是最有效的方法。在这项研究中，我们使用三重四极杆仪器评估了针对双硫酸盐代谢物的非目标检测的不同质谱方法。合成了23种甾体代谢物的双硫酸盐，并对其MS行为进行了全面研究。双硫酸盐优先离子化为二价阴离子（[M – 2H] 2–），而单阴离子（[M – H] -）的贡献很小。从[M – 2H] 2 –前体离子产生的产物离子光谱主要由HSO的损失决定4 –生成两个产物离子，即m / z 97处的离子（HSO 4 –）和对应于其余单硫酸盐片段的离子。发现其他产物离子对某些结构具有特异性。例如，发现[CH 3 + SO 3 ] -的损失对于与硫酸盐相邻的几种不饱和化合物很重要。根据双硫酸盐代谢物的常见行为，对两种选择方案进行了非靶向检测双硫酸盐代谢物的评估（i）使用m /
• Blood cell deficiency treatment method
  申请人：——

  公开号：US20030083231A1

  公开（公告）日：2003-05-01

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3&bgr;-yl)-&bgr;-D-glucopyranosiduronate, 16&agr;,3&agr;-dihydroxy-5&agr;-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene,3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  该发明涉及使用化合物治疗多种疾病，如血小板减少症、中性粒细胞减少症或放疗延迟效应。可以用于该发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-3β-基)-β-D-葡糖吡喃糖醛酸酯、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烷-5-烯、3,7,16,17-四羟基雄烷-4-烯、3,7,16,17-四羟基雄烷-1-烯或3,7,16,17-四羟基雄烷可用于治疗方法中。
• Compositions and treatment methods
  申请人：Ahlem N. Clarence

  公开号：US20060079492A1

  公开（公告）日：2006-04-13

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄甾烷可用于治疗方法。
• COMPOSITIONS AND TREATMENT METHODS-2
  申请人：Frincke James M.

  公开号：US20100222425A1

  公开（公告）日：2010-09-02

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟影响。可以在本发明中使用的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇酸酯、16α,3α-二羟基-5α-雄甾烷-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷。这些化合物可以用于治疗方法中。
• 15-THIA STEROID COMPOUNDS AND COMPOSITIONS
  申请人：Frincke James M.

  公开号：US20110218162A1

  公开（公告）日：2011-09-08

  The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy-1-O-(7,17-dioxoandrost-5-ene-3β-yl)-β-D-glucopyranosiduronate, 16α,3α-dihydroxy-5α-androstan-17-one or 3,7,16,17-tetrahydroxyandrost-5-ene, 3,7,16,17-tetrahydroxyandrost-4-ene, 3,7,16,17-tetrahydroxyandrost-1-ene or 3,7,16,17-tetrahydroxyandrostane that can be used in the treatment method.

  本发明涉及使用化合物治疗多种疾病，例如血小板减少症、中性粒细胞减少症或放射治疗的延迟效应。可用于本发明的化合物包括甲基-2,3,4-三羟基-1-O-(7,17-二氧代雄烯-5-烯-3β-基)-β-D-葡萄糖吡喃糖醇、16α,3α-二羟基-5α-雄甾酮-17-酮或3,7,16,17-四羟基雄烯-5-烯、3,7,16,17-四羟基雄烯-4-烯、3,7,16,17-四羟基雄烯-1-烯或3,7,16,17-四羟基雄烷，可用于治疗方法。